March 11, 2008 - Abbott announced today that it has received CE Mark (Conformite Europeene) approval for a 2.25 mm version of its XIENCE V Everolimus Eluting Coronary Stent System, offering physicians a smaller stent based upon the safety results and deliverability of XIENCE V.
As lesions in small vessels tend to be more complex and challenging to treat, a smaller drug eluting stent can more easily be delivered to the diseased area of the vessel, according to Abbott Vascular. The smaller stent could improve outcomes by lowering rates of reintervention in the diseased vessel, reducing rates of heart attack and death and rates of vessel renarrowing following treatment may drop, said the manufacturer.
The 2.25 mm version of the XIENCE V stent will be launched immediately in the majority of European markets and select countries in Asia and Latin America.
For more information: www.abbott.com
October 31, 2023 
